Effect of Xingnaojing Injection Combined with Sodium Valproate and Levetiracetam on the Electroencephalogram Result and Prognosis of Elderly Patients with Post-stroke Epilepsy
YU Qi
Department of Neurology, the Langfang People's Hospital, Hebei Langfang, 065000
Abstract：【Objective】To explore the effect of Xingnaojing injection combined with sodium valproate and levetiracetam on the electroencephalogram result and prognosis of elderly patients with post-stroke epilepsy (PSE). 【Methods】A total of 72 elderly patients with PSE from January 2016 to June 2017 in our hospital were enrolled for the study and randomly divided into observation group (n=36) and control group (n=36). Patients in the control group were given sodium valproate combined with levetiracetam therapy for 8 weeks. Based on that, cases in the observation group were combined with Xingnaojing injection. Electroencephalogram result, serum levels of neuron specific enolase (NSE), matrix metalloproteinase-9 (MMP-9) and tumor necrosis factor-α(TNF-α) were compared between the two groups before and after treatment. The clinical efficacy and incidence of adverse reactions were compared between the two groups. 【Results】①There were no significant differences in electroencephalogram result including epileptiform discharges and involved lead number between the two groups before treatment (P>0.05), and epileptiform discharges and involved lead number after treatment in the two groups were significantly lower than those before treatment, and the epileptic discharge and the number of leads involved in the observation group was significantly lower than those in the control group (P<0.05). ②The clinical efficacy and the total effective rate (97.2% vs. 77.8%) in the observation group were significantly better than those in the control group (P<0.05).③There were no significant differences in serum levels of NSE, MMP-9 and TNF-α between the two groups before treatment (P>0.05), and serum levels of NSE, MMP-9 and TNF-α after treatment in the two groups were significantly lower than those before treatment, and serum levels of NSE, MMP-9 and TNF-αin the observation group were significantly lower than those in the control group (P<0.05).④All patients had no serious adverse reactions. These adverse reactions were improved after symptomatic treatment and they did not affect the treatment process. There were no significant differences in the incidences of adverse reactions including nausea and vomiting, mild insomnia, abnormal sensation, abnormal liver function, drug rash between the two groups (P>0.05). 【Conclusion】Xingnaojing injection combined with sodium valproate and levetiracetam could significantly improve electroencephalogram discharges in patients with PSE, reduced serum levels of NSE, MMP-9 and TNF-α, whose clinical effect is better than sodium valproate combined with levetiracetam therapy, and it dose not increase the risk of adverse reactions.
于奇. 醒脑静联合丙戊酸钠、左乙拉西坦对老年脑卒中后癫痫患者脑电图表现及预后的影响分析[J]. 医学临床研究, 2018, 35(5): 856-859.
YU Qi. Effect of Xingnaojing Injection Combined with Sodium Valproate and Levetiracetam on the Electroencephalogram Result and Prognosis of Elderly Patients with Post-stroke Epilepsy. JOURNAL OF CLINICAL RESEARCH, 2018, 35(5): 856-859.
[1] 王萍,黄燕,汪芳.脑卒中患者亲属中医康复护理知识宣教效果评价[J].转化医学电子杂志,2017,4(8):63-64. [2] Hsieh CY, Lai EC, Yang YH, et al. Comparative stroke risk of antiepileptic drugs in patients with epilepsy[J]. Epilepsia, 2013, 54(1): 172-180. [3] 焦雨.脑卒中后继发性癫痫的临床治疗研究[J].临床医药文献电子杂志,2017,4(56):10905-10906. [4] LaFrance WC Jr, Baker GA, Duncan R, et al. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures:A staged approach:A report from the International League Against Epilepsy Nonepileptic Seizures Task Force [J]. Epilepsia, 2013, 54(11): 2005-2018. [5] Hamidou B, Aboa-Eboulé C, Durier J, et al. Prognostic value of early epileptic seizures on mortality and functional disability in acute stroke:The Dijon Stroke Registry (1985-2010)[J]. J Neurol, 2013, 260(4): 1043. [6] 李艳军,邵宏元.额叶癫痫行卡马西平联合丙戊酸钠治疗的效果研究[J].转化医学电子杂志,2016,3(2):26-27. [7] 班立丽,唐晓霞.丙戊酸钠血药浓度与抗癫痫疗效及不良反应关系研究[J].中国医院用药评价与分析,2013,13(12):1086-1089. [8] Cortes-Altamirano JL. Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug [J]. Neurol India, 2016, 64(6):1266-1275. [9] Jung S, Schindler K, Findling O, et al. Adverse effect of early epileptic seizures in patients receiving endovascular therapy for acute stroke [J]. Stroke, 2012, 43(6): 1584-1590. [10] Halliday AJ, Campbell TE, Razal JM, et al. In vivo biocompatibility and in vitro characterization of poly-lactide-co-glycolide structures containing levetiracetam, for the treatment of epilepsy [J]. J Biomed Mater Res A, 2012, 100(2): 424-431. [11] 夏志强,杜彦挺,杜光勇,等.穿刺碎吸术后辅以醒脑静注射液治疗高血压脑出血的疗效观察[J].医学临床研究,2016,33(10):2051-2053. [12] 刘宇.联合应用醒脑静与卡马西平治疗外伤性癫痫的临床效果分析[J].当代医药论丛,2015,(19):173-174. [13] 王丽玮,顾悦华,夏静,等.醒脑静注射液辅助治疗继发性癫痫的疗效及安全性的Meta分析[J].医学信息,2016,29(18):110-111. [14] 李健,沈鑫.醒脑静注射液联合德巴金治疗癫痫的临床疗效及安全性分析[J].医药前沿,2016,6(35):135-136. [15] 胡淑丽.醒脑静静脉注射联合左乙拉西坦治疗癫痫患者的疗效观察及对甲状腺功能的影响[J].国际医药卫生导报,2016,22(9):1288-1290. [16] 刘梅.醒脑静联合拉莫三嗪、丙戊酸钠治疗老年脑卒中继发性癫痫患者的疗效观察[J].辽宁中医杂志,2017,44(03):551-553. [17] NGraham NS, Crichton S, Koutroumanidis M, et al. Incidence and associations of poststroke epilepsy: the prospective South London Stroke Register [J]. Stroke, 2013, 44(3): 605. [18] Morais NM, Ranzan J, Riesgo RS. Predictors of epilepsy in children with cerebrovascular disease [J]. J Child Neurol, 2013, 28(11): 1387-1391. [19] Pezzini A, Grassi M, Del Zotto E, et al. Complications of acute stroke and the occurrence of early seizures [J].Cerebrovasc Dis, 2013, 35(5): 444-450. [20] 仲伟斌,伍国锋.醒脑静注射液对癫痫持续状态患者NSE及MMP-9的影响[J].贵州医药,2012,36(4):298-300.
2018, Vol. 35 
